Loading
Fulgent Genetics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 05 Mar 2025.
Fulgent Genetics, Inc.: what insiders have been doing
Every trade that managers of Fulgent Genetics, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Temple City, United States. It was founded in 2011. In the past year (18 October 2025 to 18 October 2026), 47 filings came from 6 insiders.
All open-market trades in the period are sales: 13 sales worth €525k, by 2 insiders, with no purchase on record. At €251k, the sale published on 21 November 2025 by Xie Jian is the largest of the period.
For context, the typical company on the same exchange (median of 5,811 companies) published 19 filings over the same period, against 47 filings here. The full history, which starts in 2021, counts 1 purchase against 92 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 322.7 m USD and net income at -60.5 m USD.
Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
297
Thresholds
n/a
Buy Volume
€2M
1 ops. · all time
Sell Volume
€6M
92 ops. · all time
Who traded when
BuySaleJian Xie15 sales
Hanlin Gao14 sales
Ming Hsieh1 sale
Paul Kim1 buy
Since the insiders bought
- -18.3%Entry US$17.90 · Close at T+365 US$14.63
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 22,052 of 24,148 companies
20.8
score / 100
Value12
Quality29
FCF yld-21%
Earn yld-10%
EV/EBITDA·
ROE-8.1%
Gross mgn41%
Net mgn-19%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$21.01
Analyst consensus
1 analysts3.00/5
US$19.00Target US$19.00(-10%)US$19.00
Income statement
RevenueUS$322.7M
Gross profitUS$130.9M41% margin
EBITDA-US$45.8M-14% margin
Net income-US$60.5M-26.0% margin
Valuation
PER (forward)-15.2x
P/Book0.6x
Beta0.93
Balance sheet & cash
Market capUS$578.1M
Total debtUS$7.7M
Free Cash Flow-US$124.2M
Debt / Equity1%
Profitability & ownership
ROE-8.1%
ROA-6.3%
% insiders37.7%
% institutions58.3%
Last declaration on 3 September 2026
Declarations297 total
4,392 shares@ US$19.590.014% mcap0.3% of flowCommon StockSEC:0001302110-26-000032:0
1,673 shares@ US$19.65640.0055% mcap2.3% of flowCommon StockSEC:0001684532-26-000013:0
2,949 shares@ US$19.810.0097% mcap0.2% of flowCommon StockSEC:0001302110-26-000030:0
939 shares@ US$19.90530.0031% mcap1.3% of flowCommon StockSEC:0001684532-26-000009:0
939 shares@ US$19.90530.0031% mcap1.3% of flowCommon StockSEC144:0001684532-26-000007
1,645 shares@ US$19.670.0055% mcap2.3% of flowCommon StockSEC:0001193125-26-321085:0
945 shares@ US$17.600.0028% mcap1.1% of flowCommon StockSEC:0001684532-26-000003:0
2,949 shares@ US$17.670.0087% mcap0.2% of flowCommon StockSEC:0001302110-26-000019:0
1,645 shares@ US$16.310.0044% mcap1.8% of flowCommon StockSEC:0001193125-26-187451:0
2,949 shares@ US$24.760.3% of flowCommon StockSEC:0001302110-26-000005:0
897 shares@ US$24.760.0042% mcap1.5% of flowCommon StockSEC:0001684532-26-000001:0
25 of 297 declarations
About Fulgent Genetics, Inc.
Fulgent Genetics, Inc. is a U.S.-based diagnostics and laboratory technology company listed on NASDAQ under the ticker FLGT, in the United States. For European investors, the company fits squarely in the healthcare and pharma ecosystem: it focuses on clinical genomics, molecular testing, anatomic pathology, and a smaller therapeutic development business. Founded in 2011, Fulgent built its franchise around two guiding ideas highlighted by management from the outset: flexibility and affordability. The company’s headquarters are in El Monte, California, where it also maintains a major portion of its laboratory and administrative footprint.
Fulgent’s core business is its laboratory services segment. That segment includes precision diagnostics, anatomic pathology, and biopharma services. Its test portfolio spans rare disease, hereditary cancer, reproductive health, and a broad set of oncology applications. Technologically, the company uses next-generation sequencing (NGS), cytogenetics, fluorescence in situ hybridization (FISH), immunohistochemistry, molecular genetics, flow cytometry, and specialist pathology interpretation. This broad panel offering is important strategically: it allows Fulgent to compete not only as a test vendor, but as a multi-technology platform capable of supporting complex clinical decision-making.
Read moreShow less
Operationally, the group runs multiple CLIA-certified laboratories across the United States, including sites in California, Texas, Massachusetts, Arizona, and Georgia. That footprint gives it national reach in the U.S. market and supports a diversified referral base. The company also serves some international demand, although its revenue remains overwhelmingly U.S.-driven. In its 2024 segment disclosure, Fulgent reported that the bulk of revenue came from the United States, with smaller contributions from China and other foreign markets.
From a competitive standpoint, Fulgent operates in a crowded and highly regulated market alongside large reference laboratories and specialized molecular diagnostics players. Its relative differentiation comes from the breadth of its test menu, its ability to develop and commercialize complex assays, and its combination of laboratory services with software-enabled workflows. The company has also been expanding through targeted acquisitions in anatomic pathology, strengthening its position in a service area that complements molecular testing. In March 2026, it completed the acquisition of Bako Diagnostics and StrataDx, adding pathology capability, proprietary PCR tests, and a broader national client base.
Recent corporate milestones also matter for the investment case. In July 2025, Fulgent received EU CE marking for FulgentExome and FulgentPLM, an important regulatory validation for its germline sequencing platform. In February 2025, Foundation Medicine announced a partnership with Fulgent to launch hereditary germline tests in the United States. Taken together, these developments suggest a company that is trying to deepen its role in precision diagnostics, broaden its technical platform, and create incremental growth opportunities beyond its legacy testing base.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
